Advertisement

Topics

Humira biosimilar performs well in Phase III trial

05:20 EST 10 Nov 2017 | SmartBrief

Boehringer Ingelheim's biosimilar Cyltezo, or adalimumab-adbm, was equivalent to Humira, or adalimumab, in treating rheumatoi -More

Original Article: Humira biosimilar performs well in Phase III trial

NEXT ARTICLE

More From BioPortfolio on "Humira biosimilar performs well in Phase III trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...